Heart Rate Variability as an Autonomic Marker of Improvement in ME/CFS in a Hydrogen Water Treatment Study

What this Trial Is About

Researchers are evaluating the use of hydrogen water, an over-the-counter magnesium-based supplement, to treat fatigue-related symptoms and improve function in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This pilot study aims to identify heart rate variability (HRV) as a biological marker that can predict who will benefit from hydrogen water treatment. The study focuses on whether hydrogen water can reduce fatigue and enhance physical function in this population. Participants will follow a 10-day graduated dosing schedule of hydrogen water, followed by a standard daily dose over 16 weeks. The treatment involves consuming hydrogen water prepared from the supplement, which is known for its antioxidant properties. Researchers expect to observe two groups among participants: those who improve and those who do not, based on their HRV measurements. During the study, participants will be assessed for fatigue severity using the Fatigue Severity Scale at 12 months. Heart rate variability will be monitored as a key biological measure to track health and well-being. The study will evaluate changes in fatigue symptoms and physical functioning over the treatment period, with safety and health status observed throughout participation, which may last up to one year.

Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS